Search results for "digoxin"
showing 3 items of 23 documents
High- versus low-dose ACE inhibition in chronic heart failure
1998
Abstract Objectives. To determine dose-related clinical and neurohumoral effects of angiotensin-converting enzyme (ACE) inhibitors in patients with chronic heart failure (CHF), we conducted a double-blind, placebo-controlled, randomized study of three doses (2.5 mg, 5 mg and 10 mg) of the long-acting ACE inhibitor imidapril. Background. The ACE inhibitors have become a cornerstone in the treatment of CHF, but whether high doses are more effective than low doses has not been fully elucidated, nor have the mechanisms involved in such a dose-related effect. Methods. In a parallel group comparison, the effects of three doses of imidapril were examined. We studied 244 patients with mild to moder…
Clinical Decision Support System To Prevent Toxicity In Patients Treated With Digoxin
2011
In this chapter, authors develop a system for prevention and detection of congestive heart failure and fibrillation. Due to its narrow therapeutic range more than 10% of the patients treated with DGX can suffer toxic effects, but it is estimated that half of the cases of digitalis toxicity could be prevented. Two multivariate models were developed to prevent digitalis toxicity.
Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older.
2021
The effectiveness of direct oral anticoagulants (DOAC) is non-inferior to vitamin K antagonists (VKA) to treat atrial fibrillation and venous thromboembolism (VTE). In this cross-sectional study, we compared older persons taking DOACs to those taking VKAs. We included ambulatory individuals ≥80 years, affiliated to Mutualité Sociale Agricole of Burgundy, who were refunded for a medical prescription in September 2017. The demographic conditions, registered chronic diseases (RCD), and number and types of prescribed drugs were compared in the DOAC group and VKA group. Of the 3190 included individuals, 1279 (40%) were prescribed DOACs and 1911 (60%) VKAs. Individuals taking VKAs were older than…